Vestcor Inc Purchases New Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC)

Vestcor Inc acquired a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 29,500 shares of the company’s stock, valued at approximately $168,000.

A number of other hedge funds have also recently bought and sold shares of the company. Lynx1 Capital Management LP raised its position in shares of C4 Therapeutics by 89.3% during the second quarter. Lynx1 Capital Management LP now owns 6,880,527 shares of the company’s stock worth $31,788,000 after acquiring an additional 3,245,865 shares during the last quarter. Wasatch Advisors LP raised its holdings in C4 Therapeutics by 17.1% during the 3rd quarter. Wasatch Advisors LP now owns 5,677,368 shares of the company’s stock worth $32,361,000 after purchasing an additional 830,218 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its position in C4 Therapeutics by 6.0% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,319,484 shares of the company’s stock valued at $7,521,000 after purchasing an additional 75,126 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of C4 Therapeutics by 331.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,201,848 shares of the company’s stock valued at $6,851,000 after purchasing an additional 923,268 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of C4 Therapeutics by 24.7% during the 3rd quarter. Wellington Management Group LLP now owns 286,041 shares of the company’s stock worth $1,630,000 after buying an additional 56,696 shares during the period. 78.81% of the stock is currently owned by institutional investors.

C4 Therapeutics Price Performance

Shares of CCCC stock opened at $4.38 on Friday. The stock has a market cap of $309.18 million, a PE ratio of -2.58 and a beta of 2.92. The stock has a 50-day moving average of $5.17 and a 200-day moving average of $5.47. C4 Therapeutics, Inc. has a one year low of $3.77 and a one year high of $11.88.

C4 Therapeutics (NASDAQ:CCCC) last issued its earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The firm had revenue of $15.36 million during the quarter, compared to the consensus estimate of $5.95 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. As a group, research analysts anticipate that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens started coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, C4 Therapeutics has a consensus rating of “Hold” and a consensus target price of $10.00.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.